Clinical trial
A Study to Assess Efficacy and Safety of Pioglitazone as Add-On Therapy to Imatinib Mesylate in CP-CML Patients in Major Molecular Response
NCT02888964 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Assess Efficacy and Safety of Pioglitazone as Add-On Therapy to Imatinib Mesylate in CP-CML Patients in Major Molecular Response
- Lead sponsor
- Versailles Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2009
- Completion date
- February 29, 2016
- Enrollment
- 27 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.